Key Highlights

  • ChronoScale (NASDAQ:CHRN) was trading down 7.83% at USD 10.01 on Friday, November 13, 2026, implying a prior close near USD 10.86 (calculated), against USD 14.77 at the October 23, 2026 close.
  • Fiscal first-quarter 2027 Revenue was USD 41.5 million, up 148% from USD 16.7 million, while the net loss was USD 42.5 million, or USD 0.29 a share, including discontinued operations.
  • Cash was only USD 15.2 million at August 31, 2026, although the company reported USD 328.2 million of customer prepayments under existing contracts.
  • Management said it is on track for USD 1 billion of annualized run-rate revenue by calendar third quarter 2027, a target the release says is not a GAAP forecast.

A 7.83% Drop With No Fresh Announcement

ChronoScale (NASDAQ:CHRN) was trading down 7.83% at USD 10.01 on Friday, November 13, 2026, in market data. No company announcement explaining the move was found. The latest company item is the fiscal first-quarter 2027 report of October 15, 2026, for the quarter ended August 31. At USD 10.01 the shares are about 32.2% below the USD 14.77 close of October 23 (calculated), and the share count of about 145.64 million implies a Market Value near USD 1.46 billion (calculated). Recent listings can trade thinly, and quoted moves can reverse. Market data also listed trailing revenue of USD 96.37 million, down 15.1%, and a trailing net loss of USD 81.67 million, figures that blend the legacy Business with the new compute operation.

From Ekso Bionics to an AI Compute Platform

The company describes itself as an accelerated compute platform for demanding AI workloads, built around large dedicated deployments. It sold its legacy Ekso Bionics business on September 30, 2026, which is why the quarter shows USD 16.1 million of discontinued operations. Revenue of USD 41.5 million came mainly from a new customer, including hardware resale arrangements, which usually carry thin margins. Cost of revenues rose 91% to USD 45.6 million, exceeding revenue. Selling and administrative costs rose to USD 20.7 million from USD 0.4 million, including USD 10.1 million of stock-based compensation. Adjusted EBITDA was USD 5.9 million against USD 9.4 million a year earlier.

The USD 1 Billion Run-Rate Plan and Its Funding Risk

Partnerships include a 50 megawatt deployment with Microsoft using Nvidia GB300 systems, a Nutanix collaboration and a three-year Baseten agreement for about 4 megawatts, due in calendar first quarter 2027. Market data also reported a USD 500 million shelf registration filed in mid-October, which would let the company sell securities later and could dilute holders. Scaling to USD 1 billion of run-rate revenue needs capital, delivery on schedule and sustained customer payments. The release gave no formal Earnings guidance. No verified sector driver for November 12 to 13 was found. The Microsoft arrangement was announced on August 27, 2026, and the Nutanix Partnership on August 18, so newer contract flow may not yet be visible in reported revenue.

Where Things Stand

Possibly, but it is unproven. ChronoScale (NASDAQ:CHRN) has contracts, USD 328.2 million of prepayments and a defined target, yet cash was USD 15.2 million at quarter end, costs exceeded revenue and a shelf registration points to possible future financing. Today's 7.83% decline has no announced cause. Next markers are execution on the Microsoft and Baseten deployments, any Capital raise and the next quarterly report, which the material found did not date. Market data showed a market value near USD 2.15 billion at the October 23 close.